Histone Acetyltransferase 1 (HAT1): A Multifunctional Modifier Rewiring Tumor Epigenetic and Metabolic Signaling

Paradigm Shift: HAT1 Dual Catalytic Activity Beyond Canonical Histone Acetylation

Lysine post-translational modifications form layered regulatory networks governing chromatin conformation and intracellular metabolic flux in mammalian cell models.
Lysine succinylation, first characterized in 2010, introduces a -2 net charge shift on modified residues, far more impactful than neutralizing acetylation events.
HAT1 has long been categorized as a type B cytoplasmic histone acetyltransferase responsible for depositing acetyl marks on histone and non-histone lysine residues.
Recent quantitative succinyl-proteomic screening redefines HAT1 biochemical capacity by identifying intrinsic succinyltransferase catalytic activity in human hepatocellular carcinoma lines.
This dual enzymatic identity establishes a molecular bridge connecting chromatin epigenetic remodeling with central carbon glycolytic pathway reprogramming in proliferative cell models.
The discovery expands existing frameworks explaining cross-talk between distinct lysine acylation marks regulated by single multifunctional modifying enzymes.

Global Proteomic Profiling Uncovers Full Spectrum of HAT1-Dependent Succinylation Substrates

CRISPR-Cas9 mediated stable HAT1 knockout HepG2 cell lines serve as paired control systems for unbiased quantitative succinyl-peptide mass spectrometry profiling.
Global proteomic datasets capture 3203 unique lysine succinylation sites distributed across 869 distinct intracellular protein substrates in wild-type hepatoma cultures.
Comparative analysis between knockout and control cell lysates identifies 324 modified lysine residues spanning 204 proteins with reduced succinylation without functional HAT1 expression.
These differential modification readouts confirm HAT1 acts as a major upstream writer shaping the landscape of cellular succinylation across nuclear and cytoplasmic compartments.
Dual in vitro recombinant enzyme assays and cellular overexpression validation independently verify direct HAT1-mediated succinylation of both histone and metabolic enzyme substrates.
The proteomic dataset supplies comprehensive substrate maps to dissect downstream epigenetic and metabolic signaling cascades modulated by HAT1 dual catalytic function.

HAT1-Mediated H3K122 Succinylation Remodels Tumor Chromatin and Transcriptional Landscapes

In vitro biochemical incubation with purified HAT1 and recombinant histone octamers validates direct covalent succinylation at histone H3 lysine 122 residues.
Genome-wide ChIP-seq mapping localizes H3K122su chromatin peaks to promoter and enhancer domains controlling tumor driver gene transcriptional programs.
Deposition of this negatively charged succinyl mark loosens histone-DNA electrostatic interactions to generate permissive open chromatin microdomains.
Elevated H3K122su occupancy correlates with increased mRNA transcription of genes mediating cell cycle progression and nutrient uptake in hepatoma cell cultures.
Loss of HAT1 catalytic activity compacts local chromatin architecture and suppresses oncogenic transcriptional networks driving sustained cell proliferation in vitro.
This histone-targeted succinylation axis represents an unreported epigenetic mechanism supporting malignant transformation through dynamic chromatin state rearrangement.

Dual HAT1 Succinylation Signaling Coordinates Glycolytic Flux via PGAM1 Metabolic Enzyme Modification

Phosphoglycerate mutase 1 (PGAM1), a rate-limiting glycolytic effector, emerges as a key cytoplasmic non-histone substrate targeted by HAT1 succinyltransferase activity.
HAT1 catalyzes stable succinylation at PGAM1 lysine 79 residues to enhance intrinsic enzyme catalytic turnover rates in cell-free biochemical reaction systems.
Elevated PGAM1 succinylation amplifies overall glycolytic carbon flux to supply nucleotide, lipid and amino acid precursors for rapid tumor cell division.
HAT1 therefore coordinates two separate oncogenic axes simultaneously: chromatin epigenetic activation and accelerated central carbon metabolic reprogramming.
Genetic ablation of endogenous HAT1 diminishes PGAM1 succinylation levels and reduces extracellular lactate secretion under normoxic culture conditions.
This dual regulatory model illustrates how single modifying enzymes synchronize nuclear transcriptional output with cytoplasmic energy metabolic pathways.

Biological Correlation and Mechanistic Implications for Tumor Cell Growth Research

Tissue microarray immunostaining of matched liver disease and normal parenchymal samples detects significantly elevated total HAT1 protein abundance in carcinoma specimens.
Stable HAT1 overexpression in low-proliferation hepatic cell lines accelerates colony formation and monolayer expansion in two-dimensional culture assays.
Conversely, HAT1 gene knockout or catalytic domain mutation restricts tumor spheroid growth under three-dimensional extracellular matrix culture conditions.
The research establishes HAT1 as a molecular node integrating epigenetic and metabolic signaling relevant to basic tumor mechanism laboratory investigation.
The dual acetyl-succinyltransferase function of HAT1 reveals widespread cross-regulation among distinct lysine acylation modification networks in mammalian proteomes.
Findings create new experimental directions for screening small molecule modulators targeting HAT1 dual enzymatic activity in cell-based research models.

Validated Histone Acetylation Recombinant Antibodies from ANT BIO PTE. LTD. for Epigenetic PTM Profiling

Site-specific recombinant rabbit monoclonal antibodies deliver high-fidelity detection of histone lysine acetylation marks required for HAT1 regulatory pathway mechanistic research.
ANT BIO PTE. LTD. supplies rigorously validated ChIP-grade anti-histone acetylation antibodies compatible with multi-platform epigenetic analytical workflows.

Catalog Table of Histone Acetylation Recombinant Antibody Products

Functional Validation of ANT BIO PTE. LTD. Histone Acetylation Recombinant Antibodies

Recombinant antibody manufacturing generates uniform antigen-binding paratopes with negligible cross-reactivity against adjacent or distinct histone modification epitopes.
Comprehensive peptide array screening confirms minimal off-target binding against methylated, succinylated and unmodified histone lysine residues within nuclear lysate matrices.
Each antibody lot undergoes multi-assay functional verification to guarantee consistent signal-to-noise ratios across repeated chromatin profiling experiments.
Validated standard laboratory workflows include Western blot quantitative detection, formalin-fixed tissue IHC, indirect cellular immunofluorescence and ChIP-seq chromatin enrichment.
These high-performance recombinant antibodies enable precise quantification of HAT1-dependent histone acetylation shifts under gene knockout or overexpression genetic perturbation.
Lot-to-lot performance consistency eliminates experimental variability in long-term serial epigenetic screening and tumor signaling mechanism research projects.

Core Fundamental Research Applications Supported by Histone Acetylation Recombinant Antibodies

1. Quantitative Western blot analysis measuring global histone acetylation fluctuations following HAT1 gene knockout, overexpression or small molecule compound treatment

2. ChIP and ChIP-seq genome-wide mapping to profile HAT1-dependent acetyl chromatin peaks across oncogenic and housekeeping gene regulatory domains

3. Immunohistochemical staining of fixed tumor tissue microarrays to correlate histone acetylation levels with endogenous HAT1 protein abundance gradients

4. Multiplex immunofluorescence co-staining to visualize co-localization of HAT1 and acetyl histone marks within proliferative cell nuclear compartments

5. Comparative epigenetic profiling of wild-type and catalytically inactive mutant HAT1 cell lines to separate acetyl vs succinylation independent signaling effects

6. Orthogonal PTM proteomic validation paired with mass spectrometry to cross-verify antibody-detected histone acetylation quantitative readouts

Global Quality Assurance and Regulatory Compliance for ANT BIO PTE. LTD. Epigenetic Research Reagents

All histone modification recombinant antibodies complete multi-platform functional validation before commercial release to deliver reproducible epigenetic profiling data.
The full reagent portfolio expands to cover lysine succinylation, fumarylation, methylation and other novel acylation targeted detection antibodies and enrichment resins.
ANT BIO PTE. LTD. operates integrated recombinant antibody expression platforms certified under ISO9001, ISO13485 and EU 98/79/EC manufacturing standards.
In-house application science teams supply customized ChIP assay protocols, peptide cross-reactivity validation datasets and curated epigenetic research reference publications.
Unified one-stop supply covers PTM antibodies, immunoaffinity microbeads and optimized pan-PTM binding buffers for complete multi-omics proteomic workflows.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs
At ANT BIO PTE. LTD., we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.

Disclaimer
This article was partially created with the assistance of artificial intelligence. If any content involves copyright or intellectual property issues, please inform us, and we promise to verify and remove it immediately.